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ABSTRACT 
OBJECTIVE: Untreated Sexually Transmitted Infections (STIs) and Bacterial vaginosis (BV) pose a 
serious health risk to mother and child. Limited data exist on the use of the BD Affirm VPIII assay as a 
point-of-care test. This study compared the BD Affirm VPIII assay to the BD MaxTM Vaginal assay 
(reference test) for the detection of BV, Trichomonas vaginalis, and Candida spp. The prevalence of 
single and co-infections are also reported here.  
 
METHODS: The study enrolled 273 pregnant women from King Edward VIII hospital in Durban. Socio-
demographic, sexual behaviour and clinical data were collected from all consenting women. The women 
provided two self-collected vaginal swabs for testing. The swabs were tested using the BD Affirm VPIII 
assay and the BD MaxTM Vaginal assay. The prevalence of BV, trichomoniasis and candidiasis was 
calculated as the percentage of women who tested positive for BV, T.vaginalis and Candida infection and 
95% confidence intervals (CIs) were calculated for these percentages using the formulas for calculating 
CIs for proportions. The number of co-infections was calculated using chi-square analysis. The diagnostic 
accuracy of the BD AffirmTM VPIII assay compared to the BD Max assay was assessed through the 
calculation of sensitivity, specificity, Negative Predictive Value (NPV) and Positive Predictive Value 
(PPV) and their respective 95% confidence intervals.  
 
RESULTS: In this study population, 85% of the participants were unmarried; however, 84% reported 
having a regular partner, and 96.3% did not use a condom regularly. The prevalence of Bacterial 
Vaginosis, Candidiasis and Trichomoniasis was 49.4%, 57.2% and 10.3%, respectively. A large 
proportion of women (78.8%) in this study did not have a discharge despite being positive for one or 
more pathogens. The BD AffirmTM VPIII assay showed a moderate sensitivity (79.8%) and specificity 
(80.3%) for diagnosing BV in all participants. The assay had an excellent specificity for Candida and T. 
vaginalis of 97.4% and 100.0%; respectively, however, it exhibited poor sensitivities of 52.9% and 
42.4%, respectively.  
 
CONCLUSION: Our findings show a higher prevalence of Bacterial Vaginosis in antenatal attendees 
than previously reported, while the prevalence of Candidiasis and Trichomoniasis was in keeping with 
previous reports. The high number of asymptomatic infections detected is of concern and indicates the 
need for the re-evaluation of the syndromic management approach, especially in the antenatal population. 
The BD AffirmTM VPIII assay was found to be unsuitable as a screening test for vaginal infections 
in pregnancy. The assay performed better as a confirmatory test and may serve useful if used in 
conjunction with other clinical parameters such as vaginal pH. 
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CHAPTER ONE - INTRODUCTION 
BACKGROUND  
According to the World Health Organizations (WHO) 2016 estimates, there are more than 1 million 
Sexually Transmitted Infections (STIs) acquired every day worldwide. Each year there are an estimated 
357 million new STI infections with 1 of 4 STIs: chlamydia (131 million), gonorrhoea (78 million), 
syphilis (5.6 million) and trichomoniasis (143 million).1 In the primary care setting, vaginitis is considered 
one of the most common gynecologic diagnosis. This condition occurs as a result of bacterial vaginosis, 
vulvovaginal candidiasis or trichomoniasis infection.2 Bacterial vaginosis, candidiasis and trichomoniasis 
in pregnancy have been associated with low birth weight, pre-term delivery and premature rupture of 
membranes.3,4,5 South Africa uses Syndromic Management guidelines for the diagnosis and treatment of 
vaginal discharges in pregnant women. Several studies have shown that syndromic management is 
inadequate for this purpose due to the high number of asymptomatic genital tract infections seen.6–10 The 
test and treat approach for vaginal discharges in pregnant women may be the best alternative.11 
In the past, diagnostic methods for Bacterial vaginosis relied on the use of clinical criteria and microscopy 
using Amsel’s Criteria or Nugent’s criteria.12 Methods for Candida included the observation of budding 
yeast cells and pseudohyphae on wet mount or a positive culture for Candida.13 Trichomonas was detected 
by wet mount, in culture, or via biochemical detection.14 Nucleic acid amplification-based assays have 
since been introduced and are widely used for detection of these pathogens. Molecular assays reduce 
error, are less laborious and have better performance.15  
In this study, we evaluated the performance of the BD Affirm VPIII Microbial Identification assay against 
the BD MaxTM Vaginal assay for the diagnosis of BV, Candidiasis and Trichomoniasis in a population of 
pregnant women. The prevalence estimates and co-infections of these pathogens are also reported through 
this study. 
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CHAPTER TWO – LITERATURE REVIEW 
2.1.1. BACTERIAL VAGINOSIS 
Bacterial vaginosis is caused by the abnormal ecology of the vaginal environment. Certain factors cause 
an alteration in the microbiome, which raises vaginal pH and which results in symptoms from none to 
very bothersome. 16 Symptomatic women typically present with vaginal discharge and or vaginal odour. 
The discharge is thin and homogenous and off-white with an unpleasant fishy odour more noticeable 
during menstruation and after sexual intercourse.16 BV is characterized by alterations in the vaginal 
environment: (1) a shift in vaginal flora from normal Lactobacillus species to predominantly facultative 
anaerobes with high bacterial diversity; (2) amines production induced by the anaerobic flora and (3)  a 
rise in vaginal pH to  greater than 4.5.16 BV is often associated with a mixed vaginitis caused by Candida 
and/or Trichomonas vaginalis and is often associated with a cervicitis (endocervical discharge and 
induced bleeding of the cervix).16 
The microbial imbalance/dysbiosis in the vaginal environment is characterised by a reduction of the 
normal lactobacilli and an increase in the concentration of anaerobic Gram-negative rods and other 
organisms. The majority of bacteria detected in women with BV are Gardnerella vaginalis, Bacteroides 
species, Peptostreptococcus species, Prevotella species, Porphyromonas species, Mycoplasma hominis, 
Ureaplasma urealyticum, Mobiluncus, Megasphaera, Sneathia, and Clostridiales species. Also common 
are Fusobacterium species and Atopobium vaginae.16 A study in 2005 by Fredericks et al. identified 35 
bacterial phylotypes that were associated with BV, with G. vaginalis being the most common. Women 
with BV had a mean of 12.6 phylotypes per sample. These newly identified organisms by polymerase 
chain reaction (PCR) were classified in the Clostridiales order and termed “BV associated bacterium 
(BVAB) 1, 2 and 3” and specific indicators of BV. 17  
The dominant lactobacilli of the normal flora are hydrogen peroxide producing and thereby prevent the 
overgrowth of anaerobes normally present in the vaginal flora. Loss of lactobacilli causes a rise in pH 
and subsequent overgrowth of vaginal anaerobes.16 These anaerobes produce large amounts of proteolytic 
carboxylase enzymes. These enzymes break down peptides into amines that are volatile and quite 
malodorous. These amines increase vaginal transudation with squamous epithelial cell exfoliation, and 
this results in the clinical features seen in BV.16 The rise in pH also facilitates the adhesion of G.vaginalis 
to the exfoliating epithelial cells. There is increasing evidence that G.vaginalis forms a biofilm to which 
other species adhere. G.vaginalis forms 90% of the biofilm with Atopobium vaginae making up the rest.16 
Desquamation results in the classic clue cells diagnostic of the disorder.16 
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2.1.2. CONSEQUENCES OF BV 
Pregnant women with BV are at a higher risk of preterm delivery as BV causes endometrial bacterial 
colonisation, postpartum fever, post-hysterectomy vaginal cuff cellulitis, plasma cell endometritis 
postabortal infection.16 BV doubles the risk of preterm delivery before gestation week 37. 18 
Alterations in estrogen and progesterone levels in pregnancy induce physiological changes, such as pH 
changes in the genital tract. 19 These physiological changes result in vaginal mucosa congestion and 
hypertrophy, which induce the growth of anaerobic bacteria and other pathogenic microorganisms. 19 
Future health implications of BV include increased susceptibility to other STIs. BV is also a risk factor 
for transmission and acquisition of Human Immunodeficiency Virus  (HIV).20  Bautista et al. in 2016 
showed that elevated cervicovaginal inflammatory cytokine levels in pregnancy-related BV might 
increase one’s vulnerability to an STI.21 Abbai et al. in 2015 showed that BV infections are associated 
with a higher incidence of Trichomonas vaginalis and Chlamydia trachomatis infections.4  
 
2.1.3. DIAGNOSIS OF BV 
BV can be diagnosed using Amsel’s criteria designed for bedside diagnosis.15 This method is simple but 
requires the use of a microscope. At least three of the four criteria must be present for a diagnosis to be 
made: (1) the presence of a thin, greyish-white homogenous discharge that coats the vaginal wall; (2) a 
vaginal pH of more than 4.5; (3) a positive whiff test, characterized as the presence of a fishy odour with 
the addition of a drop of 10 percent potassium hydroxide to vaginal discharge and (4) the presence of clue 
cells on a saline wet mount. Clue cells are epithelial cells that have coccobacilli adhering to the edges of 
the cell.15 
BV can also be diagnosed using Nugent’s criteria or Ison and Hay criteria which involves performing a 
Gram’s stain.12,22 This method requires more time, trained personnel and resources than the Amsel’s 
criteria as it relies on the actual grading of the microorganisms seen under the microscope.16 The diagnosis 
of BV using Nugent’s criteria has been the Gold standard for many years. Cytology smears and culture 
methods are not suitable for diagnosis of bacterial vaginosis as they are inaccurate in their diagnosis.16 
There are commercially available tests for the diagnosis of BV such as the OSOM BV Blue, BD AffirmTM 
VPIII and the BD MaxTM vaginal panel. The OSOM BV Blue system is a chromogenic diagnostic test 
based on detecting sialidase activity in vaginal samples. Sialidase is produced by pathogens associated 
with BV such as Gardnerella, Porphyromonas, Prevotella and Mobiluncus. The test can be used as a 
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point-of-care test and takes only 10 minutes. Bradshaw et al. in 2003 evaluated the use of the OSOM BV 
Blue test compared to Nugent's criteria and Amsel's criteria.23 The test performed well against Nugent’s 
criteria and poorly against Amsel’s criteria. A disadvantage of the BV Blue test is that it detects activity 
for bacterial vaginosis only and not for Trichomonas or Candida. 
In 1994, Briselden et al. introduced the BD Affirm VP test as a rapid, objective and automated test for 
the detection of T.vaginalis and clinically significant levels of G. vaginalis of  >5 x 105 CFU/ml; that is 
comparable to wet mount examination for clue cells and superior to wet mount examination for the 
detection of trichomonads.24 It could be used as a point-of-care test and took less than an hour to perform. 
Sheiness et al. in 1992 reported that the use of these DNA probe tests for BV had increased sensitivity 
and specificity when used with elevated pH as a diagnostic indicator.25 Briselden et al. in 1994 further 
illustrated this by showing that the BD AffirmTM VPIII assay for BV had greater sensitivity and specificity 
of 95 and 99 percent when used in conjunction with vaginal pH or wet mount than when used alone.24 A 
study in Indianapolis, USA in 2003 showed that the Affirm VP test was more sensitive in symptomatic 
women than conventional wet mount microscopy.26 Crist et al. in 2011 showed that the BD AffirmTM 
VPIII outperformed and provided faster results when compared to microscopy and culture methods for 
the diagnosis of bacterial vaginosis and yeast vaginitis.27  
Quantitative polymerase chain reaction (qPCR)-based assays such as the BD MaxTM Vaginal assay are 
based on the molecular quantification of Lactobacillus, G. vaginalis, Atopobium and other BV associated 
bacteria. qPCR is the gold standard in the quantitative analysis of nucleic acids. These tests have good 
sensitivity and specificity but are expensive to perform. Dhiman et al. showed in 2016 that qPCR has a 
better sensitivity than Nugent’s scoring system for the diagnosis of BV 28 while Sobel et al. in 2015 
showed that PCR is superior in sensitivity and specificity when compared to the BD AffirmTM VPIII 
assay.13  
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2.1.4. PREVALENCE ESTIMATES FOR BV 
Table 1. Summary of prevalence data for Bacterial Vaginosis 
Author  Organism Method Prevalence Population Country 
South Africa:       
Johnson et al, 2005 BV various - review article 24-52% antenatal South Africa 
Mlisana et al, 2012 BV Nugents criteria 52.7% clinical trial participants South Africa 
Redelinghuys et al., 2017 BV Nugents criteria 17.7% antenatal South Africa 
Abbai et al., 2015 BV Amsel's 31.0% clinical trial participants South Africa 
Torrone et al., 2018 BV 
Nugent's criteria - a meta-
analysis 41.2% clinical trial participants South Africa 
Joyisa et al., 2019 BV Nugents criteria 37.3% antenatal South Africa 
other:       
Mengistie et al, 2014 BV Nugents criteria 19.4% antenatal Ethiopia 
Olowe et al., 2014 BV Wet mount 38.0% antenatal Nigeria 
Marconi et al., 2015 BV Nugents criteria  30.1% primary health care Brazil 
Bitew et al., 2017 BV Nugents criteria 48.6% primary health care Ethiopia 
 
A study conducted by Bitew et al. in 2017 in an Ethiopian primary healthcare clinic reported a prevalence 
of 48.6%% for BV.29 Other African studies conducted in Ethiopia and Nigeria found a prevalence of 
19.4% and 38.0% for BV in antenatal populations.30,31A meta-analysis conducted by Torrone et al. in 
2018 on women participating in HIV prevention trials in Sub-Saharan Africa reported a mean prevalence 
of 41.2% for BV in South Africa.32 Similarly Mlisana et al. and Abbai et al. in 2012 and 2015 reported 
high prevalences of BV (52.7% and 31.0% respectively) for women participating in HIV prevention 
clinical trials.4,6 
A Sentinel survey conducted in South Africa in 2005 in antenatal clinic attendees found a prevalence 
ranging from 24% to 52% for BV.10 The prevalence of BV in the antenatal population in South Africa 
reported by Redelinghuys in 2017 was 17.7%.33 A recently published study in Durban, South Africa found 
a prevalence of 37.3% for BV among antenatal women.34 
 
2.2.1. CANDIDIASIS 
Vaginal candidiasis is caused by colonisation of the vagina by the yeast Candida. The most common 
species identified in vulvovaginal candidiasis (VVC) is C. albicans, with C. glabrata being the second 
most common.13 
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VVC is responsible for 80% to 90% of infections during pregnancy. Candida species have been shown 
to colonise the vagina in at least 30% of all pregnant women.35 The increased risk of VVC is likely caused 
by pregnancy-related factors such as a decrease in immunity, increased estrogen and increased glycogen 
production of the vaginal mucosa. Increased estrogen aids the adherence of yeast to vaginal mucosal cells. 
In addition, estrogen induces hyphal formation and the secretion of certain enzymes such as aspartyl 
proteinases and phospholipases. These virulence factors further enhance the colonisation of yeast in 
vaginal mucosal epithelial cells.35  
 
2.2.2. CONSEQUENCES OF CANDIDIASIS 
Typical symptoms of VVC include itching, burning, redness, swelling, and discharge. It is characterised 
by vulvar and vaginal pruritis, external dysuria, white cottage cheese discharge, and vulvovaginal 
excoriations.35 Previous studies have shown that candidiasis during pregnancy may be associated with 
premature rupture of membranes and poor pregnancy outcomes. Aguin et al. (2015) showed a higher 
preterm birth rate in women with untreated asymptomatic candidiasis compared to women without 
candidiasis.35 Although rare, Candida infection may become intra-amniotic and cause systemic 
congenital infection, cerebral candidiasis, or fetal demise.35  
 
2.2.3. DIAGNOSIS OF CANDIDIASIS 
Laboratory diagnosis of Candida infection can be made by microscopy and culture methods. The 
sensitivity of microscopy is 60-70% with many false positives and false negatives. Culture on 
Sabouraud’s glucose agar has been the gold standard for many years. However, results can take from 48 
- 96hrs. Colonies are seen on culture and confirmed by observation of budding yeast cells on gram stain. 
A Germ tube test can also be done to confirm the presence of C .albicans. The use of Chromogenic agar 
medium has also allowed the differentiation of Candida species while maintaining sensitivity. 13  
The use of DNA homology probes in tests such as the BD AffirmTM VPIII assay offers results within an 
hour. This test may be an alternative to microscopy and culture methods. The use of PCR for the detection 
of Candida was first applied in 1993, and since then numerous PCR based techniques have been 
developed for the detection of Candida.36 qPCR was first optimized by Trama et al. in 2005 for C. 
albicans, C. glabrata, C. parapsilosis and C.tropicalis.36 qPCR is now a viable option for rapid detection 
of Candida picking up low copy numbers however these tests may be more expensive and furthermore 
the detection of low levels of Candida may not indicate clinical infection. The FDA approved BD MaxTM 
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Vaginal assay is an automated qPCR method that uses a cut off value for Candida which is a superior 
indication of Candida vaginitis.  
 
2.2.4. PREVALENCE STATS FOR CANDIDA 
Table 2. Summary of prevalence data for Candida 
Author  Organism Method Prevalence Population Country 
South Africa:       
Johnson et al, 2005 CA review article 9-59% antenatal South Africa 
Garrett et al., 2017 CA Gram stain 17.6% primary health care South Africa 
other:       
Olowe et al, 2014 CA culture and germtube 36.0% antenatal Nigeria 
Marconi et al, 2015 CA Gram stain 1.4% primary health care Brazil 
Mushi et al., 2019 CA culture and MALDI-TOF 66.6% antenatal Tanzania 
Konadu et al, 2019 CA wet mount 1.4% antenatal Ghana 
Kamga et al, 2019 CA wet mount 27.8% antenatal Cameroon 
 
A study conducted by Olowe et al. in 2014 reported a prevalence of 36.0% for Candida using culture in 
a Nigerian antenatal population.31 More recent African studies in Tanzania, Ghana, and Cameroon have 
reported prevalence estimates ranging from 1.4% to 66.6% in antenatal populations.37–39 These prevalence 
estimates were obtained by culture and microscopy techniques. 
The prevalence of Candida reported by Johnson et al. 2005 in a South African sentinel survey was 
between 9 and 59% for antenatal populations.10 The studies included in the survey used microscopy and 
culture techniques for diagnosis. The last reported prevalence of Candida in South Africa was 17.6% by 
Garrett et al. in 2017 in STI clinic attendees.40  
 
2.3.1. TRICHOMONIASIS 
Trichomoniasis is caused by the flagellate protozoan Trichomonas vaginalis. T.vaginalis is considered to 
be sexually transmittable and sometimes related to low socioeconomic levels.41 Women infected with 
T.vaginalis can experience a range of symptoms, including itching frothy odorous green-grey vaginal 
discharge, and dysuria, as well as pelvic inflammatory disease and fallopian tube pathology.42 
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2.3.2. CONSEQUENCES OF TRICHOMONIASIS 
In pregnant women, T. vaginalis has been associated with an increased incidence of postpartum fever and 
endometritis, changes in cervical cell morphology and premature rupture of membranes. 14 It has been 
linked to adverse pregnancy outcomes such as low birth weight and pre-term labour.  T.vaginalis is also 
associated with an increased risk of acquiring HIV and increased vaginal shedding of HIV.42 It has been 
suggested that infection with this parasite increases maternal-to-infant transmission of HIV. Despite the 
high prevalence T. vaginalis infections, little or no attention is given to the infection during antenatal 
services as majority of the routine antenatal services focus more on HIV.43 
 
2.3.3. DIAGNOSIS OF TRICHOMONIASIS 
T.vaginalis is commonly detected using direct wet mount microscopy, culture and nucleic acid 
amplification tests. Traditionally diagnosis was made by the microscopic observation of motile protozoa 
in vaginal specimens via wet preparation. Characteristic jerky movements and the presence of flagella 
contributed to the diagnosis. For the parasite to be viable, the microscopic analysis has to be done 
timeously. This method although cost-effective has a low sensitivity as there is under-diagnosis.14 
Broth culture technique has been the gold standard for the diagnosis of T.vaginalis for many years. This 
technique involves the inoculation of a broth such as Diamond’s TYI medium and incubation for 2-7 days 
in carbon dioxide, with an additional subculture. The technique is useful when the testing laboratory is at 
a distance from the clinic; however, it is more expensive than wet mount and open to bacterial 
contamination even though antibiotics are added to the medium. Culture systems such as the BioMed 
InPouch system for T.vaginalis were developed, but this test has a slower growth due to aerobic culture 
conditions.14 Cell culture has also been used for the cultivation and detection of T.vaginalis. This 
technique offers higher sensitivity than broth culture but is more expensive, more laborious to perform 
and also prone to bacterial contamination. Some stains such as Acridine orange, Periodic-acid Schiff as 
well as Pap smears have been used in the past to identify T.vaginalis however these stains produce false 
positives and false negatives and the use of a fixative removes the ability to detect the Trichomonads 
based on motility.14  
In recent years nucleic acid amplification tests have been introduced for the detection of T.vaginalis such 
as the Gen-Probe Aptima assay, BD ProbeTec TV assay, Cepheid GeneXpert TV assay, BD MaxTM 
Vaginal assay and the BD AffirmTM VPIII assay. Molecular assays reduce error, are less laborious and 
have better performance. These tests have performed well against the conventional wet mount and culture 
systems of the past. 
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2.3.4. PREVALENCE STATS FOR TV 
Table 3. Summary of prevalence data for T.vaginalis 
Author  Organism Method Prevalence Population Country 
South Africa:       
Johnson et al, 2005 TV review article 12-52% antenatal South Africa 
Altini et al., 2006 TV review article 30% antenatal South Africa 
Mlisana et al., 2012 TV BD Probetec 20.3% clinical trial participants South Africa 
Abbai et al., 2013 TV In-pouch 10.0% clinical trial participants South Africa 
Abbai et al, 2015 TV PCR 8.3% clinical trial participants South Africa 
Moodley et al., 2015 TV BD Probetec 15.3% antenatal South Africa 
de Waaij et al., 2017 TV PCR 20.0% primary health care South Africa 
Jones et al., 2013 TV PCR 10.0% community South Africa 
Price et al., 2018 TV In-pouch 20.0% antenatal South Africa 
Torrone et al., 2018 TV NAAT, in-pouch, wet mount 8.6% clinical trial participants South Africa 
other:       
Olowe et al, 2014 TV wet mount and culture 2.0% antenatal Nigeria 
Marconi et al., 2015 TV Diamonds culture 1.4% primary health care Brazil 
Kamga et al, 2019 TV wet mount 1.0% antenatal Tanzania 
 
African studies conducted in Nigeria and Tanzania reported a prevalence of 1.0% to 2.0% for T.vaginalis 
in antenatal populations.31,39 In South Africa prevalence estimates for T.vaginalis have been obtained 
from antenatal women, high-risk women participating in clinical trials and women from the general 
population. Prevalence estimates for antenatal women ranged from 12% to 52%.8,10,42,44 The prevalence 
of T.vaginalis for women participating in HIV clinical trials ranged from 8.6% to 20.3% in South 
Africa.4,6,32,45For women from the general population the prevalence estimate was 10% for T.vaginalis.46 
 
2.4. TREATMENT BASED ON THE SYNDROMIC MANAGEMENT 
As per the WHO recommendations and the South African Department of Health maternity guidelines 
2015, South Africa follows a syndromic management approach for the treatment of STIs. The figure 
below describes the treatment regimens based on the observed clinical symptoms.   
The illustration below shows the vaginal discharge algorithm currently used. Pregnant women who 
present with abnormal vaginal discharge are treated for vaginal candidiasis on clinical indication (using 
clotrimazole) and treated syndromically for gonorrhoea, chlamydia and T.vaginalis with triple antibiotics 
(using Ceftriaxone 250mg, Azithromycin 1g and Metronidazole 2g)47.  
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Figure 1. Taken from South African Dept of Health Maternity guidelines 2015  
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Studies have shown that vaginal discharge is inaccurate in predicting pathological conditions in 
pregnancy and that asymptomatic trichomoniasis and bacterial vaginosis is a challenge in developing 
countries.48 While syndromic management has its advantages of treating patients at the first visit and 
being easy to follow, it has the following limitations: 
 
(1) it may lead to over-treatment;  
(2) increase the potential to develop antimicrobial resistance,  
(3) increase costs by the supplying of unnecessary medication6 and  
(4) Most importantly, STIs that show no symptoms are missed.49  
A study by Mlisana et al. in 2012 in South Africa showed that asymptomatic infections occur in at least 
half of all STI-infected women6 and a study by Moodley et al. in 2014 confirmed this in pregnant 
women44. Untreated STIs in pregnancy is associated with pelvic inflammatory disease (PID), tubal factor 
infertility and ectopic pregnancy.6 Inaccurate and inconsistent diagnosis of vaginosis and vaginitis in 
pregnancy apart from the serious risks mentioned causes irritating symptoms that can disrupt the quality 
of life and which can lead to continued symptoms, repeat visits and unnecessary health care system 
costs.50 
Estimates on the proportion of asymptomatic T.vaginalis infections are as high as 80%, and the Centres 
for Disease Control (CDC) recommends screening for T.vaginalis among HIV-infected women, 
particularly HIV-infected pregnant women.42 Zemouri et al. (2016) conducted a systematic review of 
published studies from 2000 to 2015 evaluating the diagnostic accuracy of the WHO Vaginal Discharge 
Flowchart where it was shown that the addition of microscopy to identify TV and BV improved the 
diagnostic accuracy, resulting in more cases being correctly treated thereby resulting in a reduction in 
overtreatment and missed cases. 9 A disadvantage of this additional testing is that microscopy is a 
specialised technique which requires more resources and skill and which may not be feasible in most 
settings.  
Johnson et al. in 2011 showed that Syndromic management programs are unlikely to have a significant 
impact on the prevalence of asymptomatic STIs in South Africa and showed the need for better screening 
programs.51 In a study by van der Eem et al. in 2016 it was shown that nearly half of the women without 
vaginal discharge and/or vulval irritation on examination tested positive for at least one STI and did not 
receive adequate treatment.7 In a 2012 South African Study, Mlisana et al. showed that most of the women 
in their study who had one or more STIs did not have clinical symptoms. They also highlighted the urgent 
need for better strategies to manage asymptomatic STIs.6 Mlisana et al. reported a total of 87.7% of 
laboratory-diagnosed STIs were asymptomatic.6 Badman et al. (2016) conducted a study in Papau New 
Guinea in 2014 where it was shown that more than 70% of pregnant women with a curable STI were 
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asymptomatic and they had concluded that the STI syndromic management based on clinical presentation 
is a poor strategy for the detection and treatment of STIs.11 
The above studies showed that Syndromic management is not adequate for the screening and treatment 
of vaginal discharge syndrome. The risks are far greater in pregnant women, and a test and treat strategy 
will be beneficial in this population. 
 
2.5 LABORATORY BASED TESTING FOR VAGINAL INFECTIONS 
The BD MaxTM Vaginal assay was used as a gold standard in this study to detect the presence of 
T.vaginalis, Candida species and Bacterial vaginosis. This assay is an FDA approved assay which 
incorporates automated DNA extraction and real-time polymerase chain reaction (PCR) for the direct, 
qualitative detection of pathogens from DNA of vaginal specimens. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The BD MaxTM instrument in the SCM Laboratory 
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The BD MaxTM Vaginal assay is an automated diagnostic test approved by the FDA for the detection of 
Vaginal pathogens associated with Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis 
from vaginal swabs. The system uses real-time polymerase chain reaction (PCR) to amplify specific 
targets and uses target-specific hybridisation probes to detect and differentiate the DNA (Illustrated in 
Figure 3.) 
 
 
Figure 3. Principle of the Real-Time Technology L.Overbergh, C.Mathieu, Molecular Diagnostics (3rd 
Edition, 2017 
 
Results are qualitative and are reported as a result for: 
(1) Bacterial Vaginosis {by using an algorithm that calculates the ratio of Lactobacillus crispatus (Limit 
of Detection (LoD): 55cfu/ml) and Lactobacillus jensenii (LoD: 510 cfu/ml), Gardnerella vaginalis (LoD: 
962 cfu/ml), Atopobium vaginae (LoD: 127 cfu/ml), BV associated bacteria-2 (LoD: 464 copies/ml) and 
Megasphaera-1 (LoD: 2265 copies/ml)},  
(2) Candida spp {which includes C.albicans (LoD:17787 cfu/ml), C.tropicalis (LoD 313 cfu/ml), 
C.parapsillosis (LoD: 30660 cfu/ml) and C.dubliniensis (LoD: 4002 cfu/ml)},  
(3) Candida glabrata (LoD: 202 cfu/ml),  
(4) Candida krusei (LoD: 1035 cfu/ml) and  
(5) Trichomonas vaginalis (LoD: 22 cells/ml) 
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In 2017 Gaydos et al. validated the accuracy of the BD MaxTM Vaginal assay using self-collected swabs 
and clinician collected swabs against Nugent’s criteria and Amsel’s criteria for BV, Chromagar and 
Sabouraud’s agar and sequencing for Candida, and wet mount and culture for T.vaginalis.  This assay 
had shown a high sensitivity and specificity of the BD MaxTM Vaginal assay compared to conventional 
methods of detection. 52 
 
2.6. POINT-OF-CARE TESTING FOR VAGINAL INFECTIONS  
The BD AffirmTM VPIII Microbial Identification assay uses two distinct single-stranded nucleic acid 
probes for each organism (a capture probe and a colour development probe) which are complementary to 
unique genetic sequences of target organisms. The test is based on the principles of nucleic acid 
hybridisation (seen in Figure 4).  
 
 
 
                                           
 
 
 
 
 
 
   
Figure 4.Showing the principle of the BD AffirmTM VPIII assay (supplied by Becton Dickinson) 
The Probe Analysis Card (PAC) has capture probes embedded on a bead for each target organism. The 
Reagent Cassette (RC) contains the colour development probes.  
 
25 
 
During sample preparation, the sample is lysed with Lysis Solution (L) and heated. Heating ruptures the 
walls of the organism and releases the nucleic acids. Buffer Solution (B) is added, which stabilises the 
nucleic acid and provides the conditions for the hybridisation process. The sample is added to the first 
well of the Reagent Cassette (RC) with the PAC, and automated processing is initiated. The BD 
MicroProbe™ Processor moves the PAC from one well of the Reagent Cassette (RC) to another. 
Hybridisation occurs on the Probe Analysis Card while it is in the first and second wells of the Reagent 
Cassette.  
The sequence of events: 
Well 1 - Hybridization of the analyte to the capture probe occurs on the bead. 
Well 2 - Hybridization of colour development probes occurs. 
Well 3 - All unbound components and probes are washed away. 
Well 4 – Binding of enzyme conjugate to the captured analyte occurs. 
Wells 5 and 6 - Unbound conjugate is washed away. 
Well 7 - Substrate is converted to a blue-coloured product if bound enzyme conjugate is present on the 
bead.  
Final step – Reading of results of colour development of each of the target organism’s beads and controls. 
Results are reported positive for: 
(1) T.vaginalis – LoD: 5 x 103 trichomonads 
(2) Gardnerella vaginalis – LoD: 2 x 105 cfu 
(3) Candida (which includes C.albicans, C.glabrata, C.kefyr, C.krusei, C.parapsillosis and C.tropicalis)- 
LoD: 1 x 104 Candida cells 
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Figure 5. Showing the BD AffirmTM VPIII instrument in the SCM Laboratory 
 
A Papau New Guinea study had further shown that a novel point-of-care testing strategy for STIs among 
pregnant women using the test and treat approach was feasible.11 The study had evaluated the Cepheid 
GeneXpert CT/NG/TV assay and the BV Blue assay as point-of-care tests in a primary health care setting, 
using self-collected vaginal swabs. The limitation of this study was that separate tests for T.vaginalis and 
BV were performed and testing for Candida was not conducted.11 Crist et al. in 2011 showed that the BD 
AffirmTM VPIII assay outperformed and provided faster results than the Amsel’s criteria, Nugent’s criteria 
and yeast culture using swab samples, in primary health care patients for the diagnosis of BV and 
Candida.53 
Cartwright et al in 2013 compared the BD AffirmTM VPIII assay to other Nucleic acid amplification tests 
(Gen-Probe assay for T.vaginalis, CAN-PCR for Candida spp, and BV-PCR for Bacterial Vaginosis) 
using vaginal swabs, in which they concluded that all three tests had to be used in combination to achieve 
an accuracy better than the BD AffirmTM VPIII assay on its own.54  
A Study by Briselden et al. showed that the BD AffirmTM VPIII assay was more sensitive than wet mount 
for the detection of T.vaginalis in swab samples.24 
All the above studies show that there is a need for a point-of-care test such as the BD AffirmTM VPIII 
assay for diagnosing vaginosis and vaginitis in a clinic setting. The BD AffirmTM VPIII assay has the 
potential to become the ideal one-assay POC as it tests all three pathogens in one cartridge simultaneously. 
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2.7. RATIONALE FOR STUDY  
Point-of-care (POC) tests can potentially bridge the gap in diagnosis of BV, T.vaginalis and Candida 
infection. These tests could lead to an improvement in health outcomes in the antenatal setting. Access to 
POC  diagnostics will lead to evidence-based treatment at the first visit.55  Additionally, POC tests are 
rapid, cost-effective and easy to perform in the clinic setting and will ensure the completion of the test 
and treat cycle.               
In this study, we have evaluated the BD AffirmTM VPIII assay as a point of care test. The BD AffirmTM 
VPIII assay is a multi-analyte, DNA probe-based system which detects Gardnerella vaginalis (BV), 
T.vaginalis and Candida spp simultaneously from a single sample. 
We have decided on this study for the following reasons: 
(1) There is limited published data on the performance of the BD AffirmTM VPIII assay against real-time 
molecular testing methods such as the BD MaxTM Vaginal assay (FDA approved).  
(2) Most published studies on the BD AffirmTM VPIII assay have recruited symptomatic patients only, in 
this study, we have sampled all eligible women, including those that do not complain of symptoms.   
(3) None of the previous studies on point-of-care tests had evaluated a test for all three vaginal infections: 
BV, Trichomoniasis and Candidiasis in a single test, nor have they used an antenatal study population. 
(4) Prevalence data on BV and STIs in the antenatal population in South Africa is lacking. BV and 
Candida were last reported in 2012 and 2005, respectively. T.vaginalis prevalence was last reported in 
2018; however, this was in an HIV-infected population only. 
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2.8. STUDY AIM:  
This study aimed to determine the diagnostic accuracy of the BD AffirmTM VPIII test when compared to 
the BD MaxTM Vaginal panel in diagnosing bacterial vaginosis, trichomoniasis and candidiasis in 
pregnant women. 
 
2.9. HYPOTHESIS: 
We hypothesise that the BD AffirmTM VPIII can be used as a screening test for the diagnosis of bacterial 
vaginosis, trichomoniasis and candidiasis in pregnant women. In addition, we hypothesise that there will 
be a high prevalence of symptomatic and asymptomatic vaginal infections in the study population. 
 
2.10. STUDY OBJECTIVES: 
1. To assess the diagnostic performance of the BD AffirmTM VPIII assay when compared to the BD 
MaxTM Vaginal assay by comparing sensitivity and specificity. 
 
2. To determine the prevalence of bacterial vaginosis, trichomoniasis and candidiasis in patients 
presenting for antenatal care. 
 
3. To determine the number of asymptomatic cases in the studied population. 
 
 
 
 
 
 
29 
 
CHAPTER THREE - METHODS 
3.1. STUDY DESIGN AND SETTING 
This was a prospective observational cross-sectional study. The study population was recruited from the 
King Edward VIII hospital in Durban, KwaZulu Natal. All patients attending the ANC clinic on the study 
days were invited to participate in the study. Recruitment continued daily until the sample size had been 
reached. Screening and enrolment was a combined visit. A questionnaire was administered to collect data 
on the women’s demographics, sexual behaviour and clinical information. During the study visit, women 
were asked to provide two self-collected vaginal swab samples.  
 
Symptomatic participants (before treatment) were characterised as those who complained of an abnormal 
vaginal discharge/dysuria or vulval itching/burning, and asymptomatic participants were characterized as 
those who did not complain of any of the above symptoms. All symptomatic women were treated as per 
the syndromic management guidelines. The guidelines advocate the use of a 2g single dose of 
metronidazole and clotrimazole vaginal pessary (single dose) or clotrimazole vaginal cream (12 hourly 
for seven days).  Participants who were asymptomatic and who tested positive for infection were not 
eligible for treatment as per the current syndromic management guidelines.  
 
3.2. ETHICAL CONSIDERATIONS AND CONFIDENTIALITY 
Ethical and human participant research approvals were obtained from the Biomedical Research Ethics 
committee (BE643/17) of the University of KwaZulu-Natal. Furthermore, this was a sub-study of a larger 
study that had already obtained gatekeeper permission, DoH approval and BREC approval (BE214/17). 
All interviews were conducted in private, and all study-related information has been stored securely. All 
records and specimens have been identified by study ID numbers only to maintain participant 
confidentiality. Only participants who had given written informed consent were included in the study.   
All participant’s samples were discarded after testing. Completed study forms have been filed in locked 
cupboards. Study risks were minimal. None of the participants complained of discomfort with the self-
collected swab collection.  
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3.3. STUDY POPULATION: 
The study cohort was made up of 273 pregnant women 18 years and older and willing to provide written 
informed consent. The study enrolled the first 273 women who met the eligibility criteria. HIV 
seropositivity was not an exclusionary criterion for the study. The recruitment process took six months to 
completion between November 2017 and May 2018. 
 
3.4. INCLUSION CRITERIA: 
 Age 18 years and older; 
 Willing to provide written informed consent; 
 Willing to provide swab samples that will be tested for vaginal pathogens. 
 
3.5. EXCLUSION CRITERIA 
 Not willing to provide informed consent 
 Women who have received antibiotic or antifungal treatment within the week.  
For all eligible participants, the following procedures took place at the enrolment visit: 
1. Obtaining written informed consent 
2. Collection of vaginal swab samples 
3. Collection of data on demographics, sexual behaviour and clinical information 
 
3.6. SAMPLE COLLECTION: 
Two self-collected vaginal swabs were obtained from each participant for testing, as illustrated in the 
Study procedure below (Figure 2). Instructions for the collection of the self-collected swabs were given 
to the study participants (refer to Appendix 4) 
The swabs were transported within two hours to the School of Clinical Medicine Laboratory, College of 
Health Sciences, Medical School campus, University of KwaZulu-Natal. At the laboratory, one vaginal 
swab was placed in the BD AffirmTM VPIII Specimen collection tube and the other in the BD MaxTM 
Vaginal assay swab diluent tube. Samples for the BD AffirmTM VPIII assay were tested immediately. 
Samples for the BD MaxTM Vaginal assay were stored at 2-8 degrees and batch tested within five days. 
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3.7. STUDY PROCEDURE: 
 
Figure 6.Flow chart of Study procedures 
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3.8. DATA COLLECTION AND MANAGEMENT 
Data at enrollment was collected by the use of a structured paper-based questionnaire administered by 
the researcher (Refer to Appendix 1). Study participants were given a unique study number sequentially 
as enrolment occurred. Clinical data were entered into a spreadsheet that contained the laboratory number 
and demographics information etc. Laboratory results for the BD AffirmTM VPIII assay were handwritten 
in logs which were later entered into the Excel spreadsheet. The BD MaxTM instrument printed reports 
from which data was entered onto the spreadsheet. All the entered results were cross-checked by a second 
person. 
 
3.9. LABORATORY TESTING 
All samples were tested by both the BD AffirmTM VPIII assay and the BD MaxTM Vaginal assay. 
 
3.9.1. BD AFFIRMTM VPIII ASSAY PROCEDURE 
The test was conducted using the manufacturer’s guidelines: 
1. The BD MicroProbe lysis block was switched ON to heat at 85oC, and the kit reagents were left 
to reach room temperature, and mixed. 
2. The Sample collection tube (with the swab in the cap) was opened, and 12 drops of lysis solution 
(L) was added to the tube using the dropper provided. 
3. The swab in the tube was mixed vigorously by swirling and moving up and down against the side 
of the tube for at least 10 secs. 
4. The tube was re-capped and placed into the lysis block to heat for 10 minutes. 
5. After removal from the lysis block, 12 drops of Buffer solution (B) was added to the tube 
(containing the swab) and mixed by flicking the tube ten times. 
6. The swabs were after that squeezed against the side of the tubes, removed, discarded, and the 
tube was re-capped with a Filter tip (FT). 
7. The MicroProbe processor was switched ON. 
8. A Reagent cassette (RC) was thereafter labelled, opened and loaded for each sample. 
9. Thereafter a Probe Analysis Card (PAC) was labelled and placed in Well 1. 
10. Four drops of Substrate solution (S) was added to well 7. 
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11. Each sample tube was matched and placed inverted into the Well 1. The sample was squeezed 
into each well. 
12. The caddy was thereafter placed on the instrument and RUN. Processing time was count down 
from 32:50. 
13. After the run, the PACs were removed, blotted lightly with a paper towel and interpreted. 
 
 
3.9.2. BD AFFIRMTM VPIII ASSAY INTERPRETATION 
The Probe Analysis Cards were inspected visually for colour development next to the target organism: 
 
 
 
 
 
 
 
3.9.3. BD MAXTM VAGINAL PANEL PROCEDURE 
Samples were processed according to the manufacturer’s guidelines. 
1. The swabs in sample buffer tubes were vortexed for 1 minute, and the swab was squeezed and 
discarded. 
2. The sample buffer tubes were uncapped and re-capped with a blue septum cap. 
3. Sample tubes were placed on the rack together with unitised reagent strips, extraction vials and 
master mix vials. 
4. Samples were logged onto the instrument, and the rack was loaded into the instrument with the 
PCR cartridge and the run initiated. An average run took 2.5 hrs. 
 
   Image by Becton Dickinson 
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3.9.4. BD MAXTM VAGINAL PANEL INTERPRETATION 
The BD MaxTM results were interpreted using the guidelines below: 
 
 
 
 
 
 
 
 
 
 
Figure 7. Interpretation of the BD MaxTM assay (BD MaxTM vaginal Panel package insert) 
 
3.9.5. BD MAXTM VAGINAL PANEL REPORT 
 
 
 
 
 
Figure 8. Shows a BD MaxTM run report generated by the instrument 
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Figure 9. Shows the Real-Time PCR Cycle Thresholds generated on a BD MaxTM Vaginal assay report 
 
3.10 DATA ANALYSIS 
The prevalence of BV, trichomoniasis and candidiasis was calculated as the percentage of women who 
tested positive for BV, T.vaginalis and Candida infection and 95% confidence intervals (CIs) were 
calculated for these percentages using the formulas for calculating CIs for proportions. The number of 
co-infections was calculated using chi-square analysis. The diagnostic accuracy of the BD AffirmTM VPIII 
assay compared to the BD MaxTM Vaginal assay was assessed through the calculation of sensitivity, 
specificity, Negative Predictive Value (NPV) and Positive Predictive Value (PPV) and their respective 
95% confidence intervals. All analyses were conducted using STATA analysis package. 
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CHAPTER FOUR – RESULTS 
4.1 CHARACTERISTICS OF THE STUDY POPULATION  
The percentage of pregnant women who tested positive for any pathogen was 81.6%. Candida was the 
most prevalent pathogen in this study, with a prevalence of 57.2%. The prevalence of Bacterial vaginosis 
was 49.4%, and T.vaginalis was detected in 10.3% of the women. 
The characteristics of the study population are described in Table 4. The median age (Q1-Q3) of the study 
population was 28.0 (24.0-33.0). Overall, the majority of the participants did not experience symptoms 
of current abnormal vaginal discharge (66.3%). The majority of the study women had a high school 
education only (66.7%), were unmarried (85.0%), and 60.8% were not cohabiting with their sex partner. 
In addition, 44.0% of the women reported not knowing if their sex partner had other partners. 
With respect to behavioural factors, 83.9% of the women had reported having a regular sex partner, 75.5% 
of the women had experienced their first sex between 15-20 years of age, and 52.4% had between 2-4 
lifetime number of sex partners. In addition, 61.9% had sometimes used a condom, and 68.9% had not 
used a condom during their last sex act. A large proportion of the women were non-smokers (95.6%) and 
did not consume alcohol (88.3%). Approximately 90.1% of the women did not perform intravaginal 
practices. 
Clinically, 57.5% of the women were in the third trimester of pregnancy, 78.8% of the women did not 
have a history of pre-term labour, 74.0% of the women did not experience a past miscarriage, and 90.5% 
of the women did not experience a past spontaneous abortion. With respect to past infections, 59.0% of 
the women did not experience symptoms of abnormal discharge in the past, 59.7% of the women had not 
been previously treated for an STI, and 30.4% were HIV negative. 
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Table 4: Demographic and behavioural characteristics of the study population according to individual infection status as determined by the BD MaxTM Vaginal 
assay 
 
  
BV neg BV pos p-
value 
TV neg TV pos p-
value 
Can neg Can pos 
p-value 
  Overall 
(n=127) (n=124) (n=243) (n=28) (n=116) (n=155) (n=273) 
age     0.896     0.711       0.113   
Mean±SD(CV%) 28.7±6.57(22.9) 28.4±5.87(20.7)   28.4±6.33(22.3) 28.6±4.99(17.4)   29.1±6.39(21.9) 27.9±6.03(21.6)   28.5±6.20(21.8) 
Median(Q1-Q3) 27.0(24.0-34.0) 28.0(24.0-33.0)   28.0(24.0-33.0) 27.0(25.0-33.3)   28.0(24.0-34.0) 27.0(23.5-32.5)   28.0(24.0-33.0) 
Min-Max 18.0-43.0 18.0-43.0   18.0-43.0 20.0-38.0   18.0-43.0 18.0-43.0   18.0-43.0 
Current abnormal vaginal discharge     0.079     0.128     < 0.001   
No 93 (73.2%) 78 (62.9%)   165 (67.9%) 15 (53.6%)   90 (77.6%) 90 (58.1%)   181 (66.3%) 
Yes 34 (26.8%) 46 (37.1%)   78 (32.1%) 13 (46.4%)   26 (22.4%) 65 (41.9%)   92 (33.7%) 
Highest level of education     0.008     0.472     0.018   
College/University 40 (31.5%) 29 (23.4%)   66 (27.2%) 5 (17.9%)   37 (31.9%) 34 (21.9%)   71 (26.0%) 
Did not attend school 2 (1.6%) 0 (0%)   2 (0.8%) 0 (0%)   2 (1.7%) 0 (0%)   2 (0.7%) 
High school 82 (64.6%) 81 (65.3%)   161 (66.3%) 20 (71.4%)   67 (57.8%) 114 (73.5%)   182 (66.7%) 
Primary school 3 (2.4%) 14 (11.3%)   14 (5.8%) 3 (10.7%)   10 (8.6%) 7 (4.5%)   18 (6.6%) 
Married     0.095     0.581     0.530   
No 101 (79.5%) 109 (87.9%)   207 (85.2%) 23 (82.1%)   97 (83.6%) 133 (85.8%)   232 (85.0%) 
Yes 25 (19.7%) 15 (12.1%)   35 (14.4%) 5 (17.9%)   19 (16.4%) 21 (13.5%)   40 (14.7%) 
Missing 1 (0.8%) 0 (0%)   1 (0.4%) 0 (0%)   0 (0%) 1 (0.6%)   1 (0.4%) 
Regular sex partner     0.146     0.174     0.842   
No 25 (19.7%) 16 (12.9%)   36 (14.8%) 7 (25.0%)   19 (16.4%) 24 (15.5%)   44 (16.1%) 
Yes 102 (80.3%) 108 (87.1%)   207 (85.2%) 21 (75.0%)   97 (83.6%) 131 (84.5%)   229 (83.9%) 
Co-habiting     0.979     0.668     0.157   
No 76 (59.8%) 74 (59.7%)   149 (61.3%) 16 (57.1%)   65 (56.0%) 100 (64.5%)   166 (60.8%) 
Yes 51 (40.2%) 50 (40.3%)   94 (38.7%) 12 (42.9%)   51 (44.0%) 55 (35.5%)   107 (39.2%) 
Age of sexual debut     0.245     0.965     0.469   
<15 8 (6.3%) 5 (4.0%)   12 (4.9%) 1 (3.6%)   7 (6.0%) 6 (3.9%)   13 (4.8%) 
>25 6 (4.7%) 1 (0.8%)   7 (2.9%) 0 (0%)   4 (3.4%) 3 (1.9%)   7 (2.6%) 
15-20 92 (72.4%) 96 (77.4%)   181 (74.5%) 23 (82.1%)   82 (70.7%) 122 (78.7%)   206 (75.5%) 
21-25 21 (16.5%) 22 (17.7%)   43 (17.7%) 4 (14.3%)   23 (19.8%) 24 (15.5%)   47 (17.2%) 
no. of lifetime sexual partners     0.563     0.161     0.555   
>4 24 (18.9%) 23 (18.5%)   44 (18.1%) 8 (28.6%)   19 (16.4%) 33 (21.3%)   52 (19.0%) 
1 40 (31.5%) 32 (25.8%)   72 (29.6%) 4 (14.3%)   35 (30.2%) 41 (26.5%)   78 (28.6%) 
2-4 63 (49.6%) 69 (55.6%)   127 (52.3%) 16 (57.1%)   62 (53.4%) 81 (52.3%)   143 (52.4%) 
Partner has other partners     0.007     0.067     0.779   
Don’t know 43 (33.9%) 61 (49.2%)   109 (44.9%) 10 (35.7%)   52 (44.8%) 67 (43.2%)   120 (44.0%) 
No 47 (37.0%) 25 (20.2%)   71 (29.2%) 5 (17.9%)   34 (29.3%) 42 (27.1%)   76 (27.8%) 
Yes 37 (29.1%) 38 (30.6%)   63 (25.9%) 13 (46.4%)   30 (25.9%) 46 (29.7%)   77 (28.2%) 
Condom use     0.980     0.350     0.048   
Always 5 (3.9%) 5 (4.0%)   9 (3.7%) 1 (3.6%)   5 (4.3%) 5 (3.2%)   10 (3.7%) 
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Never 34 (26.8%) 36 (29.0%)   70 (28.8%) 6 (21.4%)   41 (35.3%) 35 (22.6%)   76 (27.8%) 
Rarely 8 (6.3%) 8 (6.5%)   18 (7.4%) 0 (0%)   4 (3.4%) 14 (9.0%)   18 (6.6%) 
Sometimes 80 (63.0%) 75 (60.5%)   146 (60.1%) 21 (75.0%)   66 (56.9%) 101 (65.2%)   169 (61.9%) 
Condom used in last sex act     0.689     0.925     0.091   
No 88 (69.3%) 83 (66.9%)   167 (68.7%) 19 (67.9%)   86 (74.1%) 100 (64.5%)   188 (68.9%) 
Yes 39 (30.7%) 41 (33.1%)   76 (31.3%) 9 (32.1%)   30 (25.9%) 55 (35.5%)   85 (31.1%) 
Smoking     0.069     0.025     0.087   
No 124 (97.6%) 115 (92.7%)   235 (96.7%) 24 (85.7%)   108 (93.1%) 151 (97.4%)   261 (95.6%) 
Yes 3 (2.4%) 9 (7.3%)   8 (3.3%) 4 (14.3%)   8 (6.9%) 4 (2.6%)   12 (4.4%) 
Alcohol consumption     0.010     0.348     0.518   
No 118 (92.9%) 102 (82.3%)   216 (88.9%) 23 (82.1%)   104 (89.7%) 135 (87.1%)   241 (88.3%) 
Yes 9 (7.1%) 22 (17.7%)   27 (11.1%) 5 (17.9%)   12 (10.3%) 20 (12.9%)   32 (11.7%) 
Intravaginal practice     0.613     1.000     0.145   
No 117 (92.1%) 112 (90.3%)   218 (89.7%) 26 (92.9%)   108 (93.1%) 136 (87.7%)   246 (90.1%) 
Yes 10 (7.9%) 12 (9.7%)   25 (10.3%) 2 (7.1%)   8 (6.9%) 19 (12.3%)   27 (9.9%) 
Trimester of pregnancy     0.339     0.578     0.093   
1st 12 (9.4%) 16 (12.9%)   27 (11.1%) 5 (17.9%)   16 (13.8%) 16 (10.3%)   32 (11.7%) 
2nd 36 (28.3%) 42 (33.9%)   75 (30.9%) 8 (28.6%)   42 (36.2%) 41 (26.5%)   84 (30.8%) 
3rd 79 (62.2%) 66 (53.2%)   141 (58.0%) 15 (53.6%)   58 (50.0%) 98 (63.2%)   157 (57.5%) 
History of preterm labour     0.621     0.076     0.305   
No 99 (78.0%) 102 (82.3%)   195 (80.2%) 19 (67.9%)   95 (81.9%) 119 (76.8%)   215 (78.8%) 
Yes 24 (18.9%) 21 (16.9%)   43 (17.7%) 9 (32.1%)   19 (16.4%) 33 (21.3%)   53 (19.4%) 
Missing 4 (3.1%) 1 (0.8%)   5 (2.1%) 0 (0%)   2 (1.7%) 3 (1.9%)   5 (1.8%) 
Past miscarriage     0.914     0.916     0.582   
No 96 (75.6%) 93 (75.0%)   180 (74.1%) 21 (75.0%)   88 (75.9%) 113 (72.9%)   202 (74.0%) 
Yes 31 (24.4%) 31 (25.0%)   63 (25.9%) 7 (25.0%)   28 (24.1%) 42 (27.1%)   71 (26.0%) 
Past spontaneous abortion     0.784     0.324     0.042   
No 115 (90.6%) 111 (89.5%)   221 (90.9%) 24 (85.7%)   100 (86.2%) 145 (93.5%)   247 (90.5%) 
Yes 12 (9.4%) 13 (10.5%)   22 (9.1%) 4 (14.3%)   16 (13.8%) 10 (6.5%)   26 (9.5%) 
Past abnormal discharge     0.644     0.062     0.143   
No 79 (62.2%) 73 (58.9%)   148 (60.9%) 12 (42.9%)   74 (63.8%) 86 (55.5%)   161 (59.0%) 
Yes 48 (37.8%) 50 (40.3%)   94 (38.7%) 16 (57.1%)   41 (35.3%) 69 (44.5%)   111 (40.7%) 
Missing 0 (0%) 1 (0.8%)   1 (0.4%) 0 (0%)   1 (0.9%) 0 (0%)   1 (0.4%) 
Past treatment for an STI     0.536     0.140     0.307   
No 74 (58.3%) 77 (62.1%)   148 (60.9%) 13 (46.4%)   73 (62.9%) 88 (56.8%)   163 (59.7%) 
Yes 53 (41.7%) 47 (37.9%)   95 (39.1%) 15 (53.6%)   43 (37.1%) 67 (43.2%)   110 (40.3%) 
HIV status     0.653     0.011     0.045   
Negative 41 (32.3%) 35 (28.2%)   1 (0.4%) 0 (0%)   40 (34.5%) 42 (27.1%)   83 (30.4%) 
Positive 26 (20.5%) 26 (21.0%)   79 (32.5%) 3 (10.7%)   18 (15.5%) 41 (26.5%)   59 (21.6%) 
Don’t know 0 (0%) 1 (0.8%)   48 (19.8%) 11 (39.3%)   0 (0%) 1 (0.6%)   1 (0.4%) 
Missing 60 (47.2%) 62 (50.0%)   115 (47.3%) 14 (50.0%)   58 (50.0%) 71 (45.8%)   130 (47.6%) 
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4.2 FACTORS SIGNIFICANTLY ASSOCIATED WITH VAGINAL INFECTIONS 
The variables which were significantly associated with BV were having a high school level of education 
(p=0.008), not knowing if their partner had other partners (p=0.007) and not consuming alcohol (p=0.010) 
(Table 4). 
The majority of women who tested positive for Candida reported not having a current abnormal vaginal 
discharge (p<0.001), had a high school level of education only (p=0.018), used condoms sometimes 
(p=0.048) and did not experience a past spontaneous abortion (p=0.042). Within the Candida negative 
group, the majority of the women were HIV negative (p=0.045) (Table 4).  
According to the analysis, smoking and HIV status was significantly associated with T.vaginalis 
infection. The majority of the women who tested positive for T.vaginalis were non-smokers (p=0.025). 
Being HIV positive was strongly associated with T.vaginalis (p=0.011) (Table 4).  
 
4.3 PREVALENCE OF SYMPTOMATIC AND ASYMPTOMATIC INFECTIONS 
Overall, 33.7% of the women reported having a current abnormal discharge (Table 4). Of the symptomatic 
women, 37.1% tested positive for BV, 46.4% tested positive for T.vaginalis, and 41.9% tested positive 
for Candida. There were only six women who reported having a current abnormal discharge that was 
negative for BV, T.vaginalis and/or Candida. 
Of the 66.3% of the women who did not have a current abnormal vaginal discharge, 78.8% tested positive 
for either BV, T.vaginalis and/or Candida. These women were undiagnosed using the current syndromic 
management vaginal discharge algorithm.  
For Bacterial Vaginosis, 78/124 positives were asymptomatic, showing a high prevalence of 62.9%. More 
than half of the Candida and T.vaginalis infections were asymptomatic, i.e. 90/155 cases (58.1%) and 
15/28 cases (53.6%) for Candida and T.vaginalis respectively (Table 4). 
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4.4 PREVALENCE OF CO-INFECTIONS 
 
 
Table 5.Prevalence of BV, Candida and T.vaginalis co-infections by the BD MaxTM vaginal assay 
 
 
BV 
neg 
(n=127) 
pos 
(n=124) 
p-value 
Overall 
(n=273) 
T.vaginalis   0.928  
neg 113 (89.0%) 109 (87.9%)  243 (89.0%) 
pos 14 (11.0%) 14 (11.3%)  28 (10.3%) 
Missing 0 (0%) 1 (0.8%)  2 (0.7%) 
Candida   0.214  
neg 51 (40.2%) 59 (47.6%)  116 (42.5%) 
pos 76 (59.8%) 64 (51.6%)  155 (56.8%) 
Missing 0 (0%) 1 (0.8%)  2 (0.7%) 
T.vaginalis 
neg 
(n=243) 
pos 
(n=28) 
p-value 
Overall 
(n=273) 
Candida   0.224  
neg 101 (41.6%) 15 (53.6%)  116 (42.5%) 
pos 142 (58.4%) 13 (46.4%)  155 (56.8%) 
Missing 0 (0%) 0 (0%)  2 (0.7%) 
 
Of the 124 women who tested BV positive, 14 (11.3%) women also tested T.vaginalis positive. More 
than half (51.6%) of the BV positive women were co-infected with Candida. Amongst the 28 women 
who tested T.vaginalis positive, 46.4% were co-infected with Candida. Despite the high percentage of 
co-infections, there was no statistical significance (p>0.05) (Table 5). 
 
4.5 LABORATORY FINDINGS  
The full set of results of the BD AffirmTM VPIII assay and the BD MaxTM Vaginal assay are shown in 
Appendix 3. In summary, the BD AffirmTM VPIII assay generated 100% valid results for all three 
pathogens. 
For the BD MaxTM Vaginal assay, one sample was indeterminate for all three pathogens, and 21 samples 
were unresolved for BV. These samples were repeated with the same outcome. The unresolved results 
could be due to the failure of the internal sample controls as a result of inhibitors present in the sample. 
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Of the 273 pregnant women enrolled in this study, 251 were included in the BV analysis. In addition, 271 
were included for the Candida and T.vaginalis analysis, one was unresolved, and one was indeterminate 
by the BD MaxTM Vaginal assay.   
 
 
4.5.1 PERFORMANCE OF THE BD AFFIRMTM VPIII ASSAY COMPARED TO THE 
BD MAXTM VAGINAL PANEL 
 
The diagnostic performance of the BD AffirmTM VPIII in comparison to the BD MaxTM Vaginal assay for 
the three pathogens is described in Table 6. 
Of the 124 participants that were positive for BV using the BD MaxTM Vaginal assay, only 99 were 
correctly identified by the BD AffirmTM VPIII assay. This resulted in a sensitivity of 79.84% for the BD 
AffirmTM VPIII assay in diagnosing BV. In addition, 25 BV positives detected by the reference method 
were missed by the BD AffirmTM VPIII. Out of the 127 BV negatives diagnosed by the reference method, 
102 were correctly identified by the BD AffirmTM VPIII assay resulting in a specificity of 80.31% for the 
assay. There were 25 false positives diagnosed by the BD AffirmTM VPIII Assay (Table 6).  
For Candida, a total of 73/155 Candida positives identified by the BD MaxTM Vaginal assay were 
negative on the BD AffirmTM VPIII assay resulting in a poor sensitivity of 52.90%. However, 113 out of 
the 116 negatives were correctly reported as negative by the BD AffirmTM VPIII assay resulting in high 
specificity of 97.41%. There were 3 false positives for Candida (Table 6).  
Similarly, for T.vaginalis 15 out of the 28 T.vaginalis positives by the BD MaxTM Vaginal assay were 
negative with the BD AffirmTM VPIII assay resulting in a poor sensitivity of 46.43%. Despite the poor 
sensitivity, all of the 243 T.vaginalis negatives were correctly classified by the BD AffirmTM VPIII assay. 
The assay, therefore, had an excellent specificity for T.vaginalis of 100% (Table 6).  
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Table 6. Performance characteristics of the BD AffirmTM VPIII assay when compared to the BD MaxTM Vaginal assay 
 
 
 
 
 
 
        
        
  Investigational Test performance: BD Affirm
TM VP III  
Identification 
Prevalence :               
BD MaxTM Vaginal assay   
Prevalence:               
BD AffirmTM VP III assay Sensitivity Specificity PPV (95% CI) NPV (95% CI) 
ROC 
Area 
BV 49.4 (124/251)# (43.2-55.6) 47.6 (130/273) (41.7-53.6) 79.84 (71.69-86.51) 80.31(72.33-86.84) 79.84 (73.38-85.05) 80.31 (73.99-85.41) 0.80 
Candida spp 57.2 (155/271)$ (51.2-63.0) 31.5 (86/273) (26.2-37.3) 52.90 (44.73-60.96) 97.41 (92.63-99.46) 96.47 (89.86-98.83) 60.75 (56.65-64.71) 0.75 
T.vaginalis 10.3 (28/271)* (7.2-14.6) 4.8 (13/273) (2.8-8.1) 46.43 (27.51-66.13) 100.00 (98.49-100.00) 100.00 (100.00-100.00) 94.19 (91.98-95.81) 0.73 
        
        
PPV, positive predictive value; NPV, negative predictive value; BV, bacterial vaginosis; T.vaginalis, Trichomonas vaginalis   
        
Data are % (n/N) (95% confidence interval) or % (95% confidence interval)     
        
# twenty one out of the 273 tests for BV were unresolved by the BD Max Reference method, and one was indeterminate. These were therefore excluded in the analysis 
$one out of the 273 tests for Candida was unresolved by the BD Max Reference method, and one was indeterminate. These were therefore excluded in the analysis 
*one out of the 273 tests for T.vaginalis was unresolved by the BD Max Reference method, and one was indeterminate. These were therefore excluded in the analysis 
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4.5.2 PERFORMANCE OF BD AffirmTM VPIII ASSAY IN SYMPTOMATIC 
PARTICIPANTS 
For BV, in symptomatic women, the BD AffirmTM VPIII assay exhibited an improved sensitivity 
of 82.61% when compared to the overall sensitivity of 79.84% in all participants (asymptomatic 
and symptomatic) (Table 7). 
Similarly, for Candida, the BD AffirmTM VPIII assay performed better in symptomatic women 
(sensitivity 66.15%) when compared to all participants (sensitivity 52.90%). 
There was no difference in the performance of the test with respect to sensitivity for T.vaginalis 
(46.43%) (Table 7). 
 
 
Table 7. Shows the performance of the BD AffirmTM VPIII assay in symptomatic participants.  
 
  
%Sensitivity 
(overall)                      
%Sensitivity    
(symptomatic) 
%Specificity 
(overall)                        
%Specificity     
(symptomatic) 
%PPV        
(overall)                         
%PPV 
(symptomatic) 
%NPV       
(overall)                      
%NPV   
(symptomatic) 
BV 79.84 82.61 80.31 61.76 79.84 74.51 80.31 72.41 
Candida spp 52.90 66.15 97.41 96.15 96.47 97.73 60.75 46.81 
T.vaginalis 46.43 46.15 100.00 100.00 100.00 100.00 94.19 91.76 
 
Receiver Operating Characteristics (ROC) curves show the trade-off between sensitivity and 
specificity for a diagnostic test, ie.test accuracy. The ROC curve analysis for the BD AffirmTM 
VPIII assay in diagnosing BV was fairly good (area=0.80). The test is, therefore fairly accurate 
in distinguishing infected from uninfected individuals for BV (Figure 10a). 
The ROC curves for Candida (Figure 10b) and T.vaginalis (Figure 10c) were shown to be fair 
(area=0.75 and 0.73, respectively). The test is therefore not very accurate in differentiating 
infected from uninfected patients for these two pathogens and therefore may not be suitable to 
use alone as a point-of-care test. 
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a.                                                                                          b.  
 
                                c. 
 
     
 
 
 
 
 
Figure 10. Receiving Operating Characteristic (ROC) curve analysis for (a) BV, (b) Candida 
species, and (c) T. vaginalis 
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CHAPTER FIVE 
5.1 DISCUSSION 
The correct diagnosis and treatment of Bacterial Vaginosis, Candidiasis and Trichomoniasis are 
vital in pregnancy as poor diagnosis and treatment results in poor pregnancy outcomes. This study 
observed a higher prevalence of BV (49.4%) in pregnant women in South Africa than previously 
reported (37.3%).33 The high prevalence of BV observed in our population could be attributed to 
the following socio-demographic and behavioural characteristics. The majority of women 
(55.6%) in the BV positive group had reported having between 2-4 lifetime sex partners. 
Increased number of lifetime sex partners has been shown to be associated with an increased risk 
of vaginal infections.4 In addition, close to 80% of the BV positive women had experienced their 
first sexual act at the age of 15-20 years. Early age of sexual debut could be associated with 
vaginal infections. The lack of condom use was also higher in BV positive women. The variables 
which were significantly associated with BV in our study population were having a high school 
level of education (p=0.008), not knowing if their partner had other partners (p=0.007) and not 
consuming alcohol (p=0.010). A study by Yzeiraj-Kalemaj et al. in 2013 found a low level of 
education to be significantly associated with positive BV status amongst pregnant women, which 
differs from the findings of the present study.56 In the current study a higher proportion of women 
had a high school level of education, and this could have contributed to of a higher prevalence of 
BV infection in this group. In this study women who reported not knowing if their partners had 
other partners were at higher risk for BV. Abbai et al. in 2018 reported similar findings.57 In this 
study, we found that alcohol consumption was not a risk factor for BV infection. Our findings 
differ from the study by Francis et al. in 2015.58 However, the current study consisted of a larger 
proportion of non-alcohol users which could have contributed to the negative association 
observed.  
 
The observed prevalence estimates for Candida spp. in this study was 57.2%. The high prevalence 
of Candida could be due to the fact that during pregnancy estrogen levels are high and these high 
levels provides a conducive environment for the growth of Candida spp.38 
The majority of women who tested positive for Candida spp. in this study reported not having a 
current abnormal vaginal discharge (p<0.001), had a high school level of education only 
(p=0.018), used condoms sometimes (p=0.048) and did not experience a past spontaneous 
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abortion (p=0.042). Within the Candida spp. negative group, the majority of the women were 
HIV negative (p=0.045). Konadu et al. in 2019 reported a high proportion of Candida positive 
women to be asymptomatic confirming the findings of our study.38 A previous study conducted 
by Faraji et al. in 2012 found a significant association between low level of education (non-
tertiary) and VVC.59 This confirms the findings of our study which found a significant association 
between non-tertiary education and Candida infection. In our study majority of women who were 
positive for Candida reported using condoms “sometimes”. However, a study conducted by 
Djohan et al. in 2019 found a protective association between condom use and the risk for VVC.60 
A study by Liu et al. in 2018 found a positive association between VVC and women who have 
experienced spontaneous abortion.61The findings of our study differ since we found that majority 
of the Candida positive women did not report previous spontaneous abortion. In our study 
population there were very few events of condom use and past experience of spontaneous abortion 
which could have resulted in a negative association with Candida infection. In this study we found 
a significant association between HIV negative status and Candida infection. However, there was 
a large proportion of missing data for HIV status thereby negating comparisons with previously 
published studies. 
 
The prevalence of T.vaginalis in this study was 10.3%. This was similar to other cohorts of South 
African pregnant women. 10,32 The majority of the women who tested positive for T.vaginalis on 
this study were non-smokers (p=0.025). This was an expected finding since our study population 
was pregnant women. Previous studies which found a significant association between smoking 
and T.vaginalis infection were conducted in non-pregnant populations.62,63 In our study being HIV 
positive was strongly associated with T.vaginalis (p=0.011). Despite a large proportion of missing 
data on HIV status our results were similar to a study by Lockhart et al. in 2019.63 
 
Syndromic management has its advantages of treating patients at the first visit and being easy to 
follow. However previous studies have shown that the Syndromic Management guidelines are no 
longer adequate for the treatment of STIs in women, as vaginal discharge alone is a poor predictor 
and asymptomatic infections are missed.6,7,9,11,51 In this study, approximately less than half of the 
women who tested positive for BV, Candida spp. and T.vaginalis were symptomatic (37.1%, 
41.9% and 46.4%, respectively) and this is consistent with previous reports of a high burden of 
asymptomatic STIs.6,44. If a test and treat approach had been used, 78.82% of the women in the 
current study with undiagnosed infections could have been adequately treated. 
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Alternate strategies are required, such as the test and treat approach, particularly in pregnant 
women.  
The current guidelines for maternity care in South Africa advocate essential screening tests for 
the first antenatal visit.  This includes tests for Syphilis, Rhesus Blood group, Hemoglobin, HIV, 
and Urine protein and glucose. In order to improve maternity healthcare in South Africa, it is 
important that this list is revisited with the addition of POCTs for an infection that impacts on 
pregnancy outcome. With recent technology, POCT can now be performed at the clinic, the test 
results are available within 1-2 hours and treatment can be initiated on the same day. An added 
advantage of POC testing is that it reduces the risk of over-treating, which results in increased 
microbial resistance, particularly for T.vaginalis infection. 
 
POCTs have the potential to bridge the gap in the diagnosis of vaginosis and vaginitis, especially 
in high priority populations such as in pregnant women.  It is well noted that the cost of POCTs 
is a barrier to use.64 Therefore, manufacturers of the POCTs need to be engaged by policymakers 
on reducing the costs of these assays, especially with the promise of large-scale implementation. 
Previous studies on POCTs for vaginal pathogens have shown that the BD AffirmTM VPIII assay 
has the potential to become the ideal one-assay POCT for diagnosing vaginosis and vaginitis in a 
clinic setting.24,53,54 To date there is no other single cartridge test that detects BV, Candida spp. 
and T. vaginalis. The test is therefore superior, with the added advantage of being easy to perform 
and having a short time-to-detection. The current study compared the BD AffirmTM VPIII assay 
to a leading Real-Time molecular laboratory-based assay, the BD MaxTM Vaginal assay. The BD 
MaxTM Vaginal assay has been FDA approved since 2016 and uses a newer, more updated 
technology for the detection of BV, Candida spp. and T.vaginalis.  
 
In our study, the assay showed a moderate sensitivity for BV (79.84%). The moderate sensitivity 
could be due to the following reasons (1) The BD MaxTM Vaginal assay (reference) has a lower 
limit of detection for G.vaginalis than the BD AffirmTM VPIII and would, therefore, pick up more 
positives; (2) The BD MaxTM Vaginal assay uses a ratio to interpret BV positives and this ratio is 
based on the presence of G.vaginalis but also on other organisms associated with BV; (3) The BD 
AffirmTM VPIII assay measures the DNA directly from the samples (absolute counts) without 
amplification while the BD MaxTM Vaginal assay measures amplified DNA which is more 
accurate. Amplification methods of detection have been shown to be more sensitive versus 
absolute counts.50 
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 The low specificity for BV by the BD AffirmTM VPIII could be due to the fact that since the 
development of the assay there have been newer more diverse populations of bacteria implicated 
in BV rather than G.vaginalis alone, such as Mobiluncus spp, Bacteroides spp, Atopobium spp.  
Thompson et al. 2019 also reported a lower specificity for the BD AffirmTM VPIII when compared 
to the BD MaxTM Vaginal assay, suggesting that the Affirm detects G.vaginalis only whereas the 
BD MaxTM Vaginal assay detects a combination of microorganisms.65 
 
The BD AffirmTM VPIII assay showed a poor sensitivity for Candida spp (52.90%). This poor 
sensitivity could be attributed to the non-amplification nature of the BD AffirmTM VPIII assay. 
The test did however exhibit an excellent specificity (97.41%) for Candida spp since the assay 
did not report on false positives. Similarly, the BD AffirmTM VPIII assay showed a poor sensitivity 
for T.vaginalis.(46.43%) and an excellent specificity (100%). The poor sensitivity of the BD 
AffirmTM VPIII assay for T.vaginalis could be due to the higher LoD (5 x 103 trichomonads) to 
be classified as positive whereas the BD MaxTM Vaginal assay has a LoD of 22 cells/ml. Poor 
sensitivity of the BD AffirmTM VPIII assay for T.vaginalis detection was also illustrated in 2011 
by Andrea et al. when compared to another molecular amplification assay.66 The poor sensitivity 
of the BD AffirmTM VPIII test indicates that the test cannot be used as a screening test but the 
excellent specificity for Candida spp. and T.vaginalis indicates that the test can be used as a 
confirmatory test when vaginitis is suspected.  
 
Our study has also shown an improved sensitivity of the BD AffirmTM VPIII assay when only 
symptomatic participants were analysed. This is consistent with findings by Haywood et al. in 
2004 where it was concluded that symptomatic women were more likely to be positive by the BD 
AffirmTM VPIII test than asymptomatic women using this test.26 
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5.2. CONCLUSIONS 
In summary, this study found a high prevalence of BV in the antenatal population, with previously 
reported rates for Candida and T.vaginalis infection. The study also found a very high proportion 
of women with asymptomatic BV and vaginitis attending antenatal care. Lastly, urgent 
intervention is required to address the inadequacy of syndromic management in this high priority 
population. 
Our analysis showed that the BD AffirmTM VPIII assay has a lower diagnostic accuracy when 
compared to the BD MaxTM Vaginal assay. These findings are similar to the findings of Cartwright 
et al. in 2013, where the BD AffirmTM VPIII assay was shown to be less sensitive than molecular 
methods for the detection of BV, Candida and T.vaginalis .54  We conclude that the BD AffirmTM 
VPIII assay is currently unsuitable as a screening test. However, the test may be useful as a 
confirmatory test when used in conjunction with clinical criteria such as increased pH as 
previously reported.24 
 
 
5.3. RECOMMENDATIONS 
The BD Affirm test was developed in the 1990s, and further enhancements are required for 
increased performance and acceptance as a point-of-care test. The test could be optimised to 
include other pathogens implicated in BV, and although easier to perform than a wet mount, the 
test requires skilled staff as there are many pre-analytical steps which can introduce error. If the 
system included the dispensing of reagents in the automation, the test would be more widely 
accepted as a point-of-care test. However, this assay is still the only point of care assay on the 
market that simultaneously detects BV, Candida spp. and T.vaginalis in a single cartridge. 
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5.4. LIMITATIONS 
This study had the following limitations. Firstly, the study was only conducted at one antenatal 
clinic, which is not a representation of the whole antenatal population in South Africa. However, 
clinic attendees at King Edward VIII Hospital are from the greater Durban area and are therefore 
representative of a general population. Secondly, the presence of cervical pathogens, such as 
Chlamydia trachomatis and Neisseria gonorrhoeae, were not investigated in this study. These 
pathogens may have contributed to the abnormal vaginal discharge reported by the study women 
since 6 women reported discharge but did not test positive for any of the three pathogens 
investigated in this study. Thirdly, the women were not followed up to assess test-of-cure and the 
implications of infection on pregnancy outcomes. Following up the women until cure would have 
allowed us to shed some light on the usefulness of syndromic management in this population. 
However more than 70% of the women in this study were asymptomatic and would have been 
missed by syndromic management.  
Despite these limitations, the strengths of the study are as follows (1) this study has provided data 
on the prevalence of BV, Candida and T.vaginalis in an antenatal population in which there is 
currently lack of data in South Africa and (2) the study has provided evidence that a large 
proportion of pregnant women who are asymptomatic carry infection, which re-affirms the 
limitation of the syndromic management approach, and lastly (3) this study was the first to report 
on the performance of the BD AffirmTM VPIII POCT in an antenatal population both locally and 
globally. 
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APPENDIX 3: 
Appendix    :  Summary of the BD AffirmTM VPIII assay and BD MaxTM Vaginal assay results. 
Sample ID Sym/Asym Max BV 
Affirm 
G.vag Max Candida 
Affirm 
Candida Max TV 
Affirm 
T.vag 
V001 Sym pos neg neg neg pos neg 
V002 Asym neg neg neg neg neg neg 
V003 Asym pos pos pos neg neg neg 
V004 Asym neg pos pos neg neg neg 
V005 Asym neg neg neg neg neg neg 
V006 Sym neg neg pos pos neg neg 
V007 Sym neg neg pos neg neg neg 
V008 Sym neg pos pos pos neg neg 
V009 Asym pos pos neg neg neg neg 
V010 Sym pos pos pos pos neg neg 
V011 Sym pos pos pos pos neg neg 
V012 Asym UNR pos pos pos neg neg 
V013 Asym pos pos neg neg neg neg 
V014 Sym pos pos neg neg neg neg 
V015 Sym UNR neg pos pos neg neg 
V016 Sym neg pos neg neg neg neg 
V017 Sym pos pos neg neg pos pos 
V018 Asym pos neg neg neg neg neg 
V019 Asym pos pos neg neg neg neg 
V020 Asym neg neg neg neg neg neg 
V021 Asym pos pos pos pos pos pos 
V022 Asym neg neg pos neg neg neg 
V023 Asym neg neg neg neg neg neg 
V024 Asym pos neg neg neg neg neg 
V025 Asym neg neg neg neg neg neg 
V026 Asym neg neg pos pos neg neg 
V027 Asym pos pos neg neg neg neg 
V028 Asym neg neg pos pos neg neg 
V029 Sym neg neg pos pos neg neg 
V030 Asym neg neg pos neg pos neg 
V031 Asym pos pos neg neg neg neg 
V032 Asym pos pos pos neg neg neg 
V033 Asym neg neg pos neg neg neg 
V034 Sym neg neg pos neg neg neg 
V035 Sym pos pos pos pos neg neg 
V036 Asym neg neg neg neg neg neg 
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V037 Sym pos pos neg neg neg neg 
V038 Asym neg neg pos neg pos neg 
V039 Asym neg neg pos pos neg neg 
V040 Asym neg neg neg neg neg neg 
V041 Asym pos neg pos pos neg neg 
V042 Sym pos pos pos pos neg neg 
V043 Asym neg neg neg neg neg neg 
V044 Asym pos pos neg neg pos pos 
V045 Sym pos pos neg neg neg neg 
V046 Sym UNR neg neg neg neg neg 
V047 Asym pos pos neg neg neg neg 
V048 Asym pos pos neg neg neg neg 
V049 Asym neg neg pos neg neg neg 
V050 Asym pos pos pos neg neg neg 
V051 Sym pos neg pos pos pos neg 
V052 Asym pos pos pos neg neg neg 
V053 Sym pos pos pos pos neg neg 
V054 Asym neg pos pos neg neg neg 
V055 Asym pos pos neg neg pos pos 
V056 Sym neg pos pos neg neg neg 
V057 Sym pos pos pos neg neg neg 
V058 Asym pos pos neg neg neg neg 
V059 Asym neg neg neg neg neg neg 
V060 Sym pos pos pos pos neg neg 
V061 Asym pos pos pos pos neg neg 
V062 Asym pos pos neg neg neg neg 
V063 Asym neg neg neg neg neg neg 
V064 Asym pos pos neg neg neg neg 
V065 Asym neg neg neg neg neg neg 
V066 Sym pos neg neg neg neg neg 
V067 Asym pos pos neg neg neg neg 
V068 Asym pos pos pos neg neg neg 
V069 Sym pos pos neg neg neg neg 
V070 Asym neg neg neg neg neg neg 
V071 Sym neg neg neg neg neg neg 
V072 Sym neg pos pos neg neg neg 
V073 Asym pos neg pos pos neg neg 
V074 Sym pos pos pos neg neg neg 
V075 Asym neg neg pos neg neg neg 
V076 Asym pos pos neg neg neg neg 
V077 Sym pos pos pos pos neg neg 
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V078 Asym neg pos pos pos neg neg 
V079 Asym neg neg pos neg pos neg 
V080 Asym pos pos neg neg neg neg 
V081 Sym pos pos pos neg neg neg 
V082 Asym neg neg neg neg neg neg 
V083 Asym pos pos pos neg neg neg 
V084 Asym pos pos pos neg neg neg 
V085 Asym neg neg neg neg neg neg 
V086 Sym neg neg pos pos pos neg 
V087 Asym neg pos pos neg neg neg 
V088 Asym pos pos pos neg pos neg 
V089 Asym neg neg neg neg neg neg 
V090 Asym pos pos neg neg neg neg 
V091 Asym UNR neg neg neg neg neg 
V092 Asym pos pos neg neg neg neg 
V093 Asym neg neg pos pos neg neg 
V094 Sym UNR pos pos pos neg neg 
V095 Asym neg pos pos pos neg neg 
V096 Asym neg pos neg neg neg neg 
V097 Asym neg neg neg neg pos pos 
V098 Sym pos pos neg neg neg neg 
V099 Asym pos neg UNR neg UNR neg 
V100 Asym neg neg neg neg neg neg 
V101 Asym neg neg pos pos neg neg 
V102 Sym neg neg pos pos neg neg 
V103 Asym pos neg neg neg neg neg 
V104 Asym pos neg pos neg neg neg 
V105 Asym neg neg pos neg neg neg 
V106 Asym neg pos pos pos neg neg 
V107 Asym neg neg pos pos neg neg 
V108 Asym UNR pos neg neg neg neg 
V109 Asym pos neg neg neg neg neg 
V110 Asym UNR neg pos pos neg neg 
V111 Sym pos neg neg neg neg neg 
V112 Sym pos neg pos pos neg neg 
V113 Asym neg pos neg neg neg neg 
V114 Asym neg neg pos pos neg neg 
V115 Asym neg neg neg neg neg neg 
V116 Sym pos pos pos neg neg neg 
V117 Asym neg neg pos pos neg neg 
V118 Asym neg neg pos pos neg neg 
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V119 Asym neg neg pos neg neg neg 
V120 Sym UNR pos pos neg neg neg 
V121 Asym pos pos pos neg neg neg 
V122 Asym neg neg neg neg pos pos 
V123 Asym pos pos pos neg neg neg 
V124 Asym pos pos neg neg neg neg 
V125 Asym neg neg pos neg neg neg 
V126 Asym pos pos pos neg neg neg 
V127 Asym neg neg pos neg neg neg 
V128 Sym pos neg pos pos pos neg 
V129 Asym neg neg pos pos neg neg 
V130 Asym neg neg neg neg neg neg 
V131 Sym pos pos pos neg neg neg 
V132 Asym neg neg pos neg neg neg 
V133 Sym neg neg neg neg neg neg 
V134 Sym neg neg pos neg neg neg 
V135 Asym neg neg pos pos neg neg 
V136 Sym pos pos pos neg neg neg 
V137 Sym pos neg neg neg neg neg 
V138 Asym pos pos pos neg neg neg 
V139 Sym pos pos pos neg neg neg 
V140 Asym neg neg pos pos neg neg 
V141 Asym neg pos pos neg neg neg 
V142 Sym pos pos neg neg pos neg 
V143 Sym neg pos pos pos neg neg 
V144 Asym neg pos pos neg neg neg 
V145 Asym neg neg pos neg neg neg 
V146 Asym pos pos neg neg neg neg 
V147 Asym neg neg neg neg neg neg 
V148 Asym pos pos neg neg neg neg 
V149 Asym neg neg pos neg neg neg 
V150 Asym pos pos pos neg neg neg 
V151 Asym neg neg neg neg neg neg 
V152 Asym neg neg neg neg neg neg 
V153 Sym pos pos pos neg neg neg 
V154 Sym pos pos pos pos pos pos 
V155 Asym neg neg pos neg neg neg 
V156 Asym pos pos neg neg neg neg 
V157 Asym pos pos pos pos neg neg 
V158 Asym pos pos pos neg neg neg 
V159 Asym pos pos neg neg neg neg 
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V160 Asym neg neg pos neg neg neg 
V161 Asym pos pos neg neg neg neg 
V162 Asym pos pos pos neg neg neg 
V163 Sym neg neg pos pos neg neg 
V164 Asym pos pos pos pos pos pos 
V165 Asym neg neg pos neg neg neg 
V166 Asym neg neg neg neg pos neg 
V167 Sym pos pos pos pos neg neg 
V168 Sym pos pos pos neg pos neg 
V169 Sym UNR pos pos pos neg neg 
V170 Sym pos pos pos pos neg neg 
V171 Asym pos pos pos pos neg neg 
V172 Sym pos pos neg neg neg neg 
V173 Sym pos neg pos neg neg neg 
V174 Asym neg neg neg neg neg neg 
V175 Asym neg neg neg neg neg neg 
V176 Sym pos pos pos pos neg neg 
V177 Asym pos pos neg neg neg neg 
V178 Asym neg pos pos pos neg neg 
V179 Sym pos pos pos pos neg neg 
V180 Asym neg neg neg neg pos neg 
V181 Asym neg neg neg neg neg neg 
V182 Asym pos neg pos neg neg neg 
V183 Asym neg neg neg neg neg neg 
V184 Asym neg neg neg neg neg neg 
V185 Asym neg pos neg neg neg neg 
V186 Asym pos neg neg neg neg neg 
V187 Sym neg neg pos pos neg neg 
V188 Asym pos pos pos neg neg neg 
V189 Asym neg neg neg neg neg neg 
V190 Asym UNR neg pos pos neg neg 
V191 Sym UNR neg pos pos neg neg 
V192 Sym UNR neg pos pos neg neg 
V193 Sym neg pos neg neg pos pos 
V194 Asym neg neg pos neg neg neg 
V195 Sym neg neg pos pos neg neg 
V196 Sym neg neg pos pos neg neg 
V197 Sym neg pos pos pos neg neg 
V198 Sym neg neg neg neg neg neg 
V199 Asym neg neg pos neg neg neg 
V200 Asym pos pos pos neg neg neg 
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V201 Asym neg neg pos neg neg neg 
V202 Sym neg pos pos pos neg neg 
V203 Asym pos neg neg neg neg neg 
V204 Asym neg neg pos pos pos pos 
V205 Sym neg neg pos pos neg neg 
V206 Sym IND x2 neg IND pos IND neg 
V207 Sym pos pos pos pos neg neg 
V208 Asym neg neg neg neg neg neg 
V209 Sym neg neg pos pos neg neg 
V210 Asym pos neg pos pos neg neg 
V211 Asym pos pos pos pos neg neg 
V212 Asym pos pos pos pos neg neg 
V213 Asym pos pos neg neg neg neg 
V214 Asym UNR neg neg neg neg neg 
V215 Asym pos pos neg neg neg neg 
V216 Asym neg neg neg neg pos neg 
V217 Sym pos pos neg neg pos neg 
V218 Asym pos neg neg pos neg neg 
V219 Asym pos neg pos pos neg neg 
V220 Asym pos neg neg neg neg neg 
V221 Asym neg neg neg neg neg neg 
V222 Sym pos pos pos neg neg neg 
V223 Asym pos pos neg neg neg neg 
V224 Asym pos pos neg neg neg neg 
V225 Asym neg neg pos pos neg neg 
V226 Asym UNR neg neg neg neg neg 
V227 Sym pos pos pos neg neg neg 
V228 Asym neg neg pos neg neg neg 
V229 Sym pos pos pos neg neg neg 
V230 Sym pos pos pos neg neg neg 
V231 Sym neg neg neg pos neg neg 
V232 Asym neg neg pos neg neg neg 
V233 Sym neg pos pos pos neg neg 
V234 Asym pos pos neg neg neg neg 
V235 Sym neg pos pos pos pos pos 
V236 Sym neg neg pos pos neg neg 
V237 Sym UNR pos neg neg neg neg 
V238 Asym UNR neg pos neg neg neg 
V239 Sym pos pos neg neg neg neg 
V240 Sym pos pos pos neg neg neg 
V241 Sym neg pos neg neg pos pos 
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V242 Sym UNR neg pos pos neg neg 
V243 Asym neg neg neg neg neg neg 
V244 Asym pos pos pos neg neg neg 
V245 Asym neg neg pos pos neg neg 
V246 Asym pos pos neg neg neg neg 
V247 Sym neg pos neg neg neg neg 
V248 Asym pos pos pos pos neg neg 
V249 Sym neg neg neg neg pos pos 
V250 Sym neg pos pos pos neg neg 
V251 Asym neg neg pos pos neg neg 
V252 Sym neg neg pos pos neg neg 
V253 Sym UNR neg pos neg neg neg 
V254 Asym neg neg pos pos neg neg 
V255 Asym pos neg pos neg neg neg 
V256 Asym pos pos neg neg neg neg 
V257 Sym UNR neg pos pos neg neg 
V258 Asym neg neg neg neg neg neg 
V259 Asym neg neg neg pos neg neg 
V260 Asym pos pos neg neg neg neg 
V261 Asym neg neg pos neg neg neg 
V262 Sym neg neg pos pos neg neg 
V263 Asym UNR neg pos pos neg neg 
V281 Asym neg neg neg neg neg neg 
V282 Asym pos pos neg neg neg neg 
V283 Asym pos pos neg neg neg neg 
V284 Asym neg neg pos pos neg neg 
V285 Asym UNR neg pos pos neg neg 
V286 Asym pos pos neg neg neg neg 
V287 Sym pos pos neg neg neg neg 
V288 Asym neg neg pos neg neg neg 
V289 Asym neg neg neg neg neg neg 
V290 Asym pos neg neg neg pos neg 
Note. BD Max Candida positive results shown were positive for either of the Candida groupings 
(C.group / C.glabrata / C.krusei) 
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